Christi Shaw Net Worth

The estimated Net Worth of Christi Shaw is at least $2.54 Milion dollars as of 11 December 2020. Ms. Shaw owns over 14,286 units of Avantor stock worth over $304,594 and over the last 8 years she sold AVTR stock worth over $1,960,495. In addition, she makes $278,129 as Independent Director at Avantor.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Shaw AVTR stock SEC Form 4 insiders trading

Christi has made over 5 trades of the Avantor stock since 2018, according to the Form 4 filled with the SEC. Most recently she sold 14,286 units of AVTR stock worth $381,150 on 11 December 2020.

The largest trade she's ever made was selling 14,286 units of Avantor stock on 11 December 2020 worth over $381,150. On average, Christi trades about 4,445 units every 73 days since 2017. As of 11 December 2020 she still owns at least 11,319 units of Avantor stock.

You can see the complete history of Ms. Shaw stock trades at the bottom of the page.

Christi Shaw biography

Christi Shaw is Independent Director of the company. Ms. Shaw has served on our board since November 2018 and is a member of the Compensation and Human Resources Committee and the Nominating and Governance Committee. Ms. Shaw is the Chief Executive Officer of Kite, a Gilead company specializing in the development of cancer immunotherapies, a position she has held since July 2019. From April 2017 to June 2019, Ms. Shaw served as Senior Vice President of Eli Lilly Company, a global healthcare company, and President of Lilly Bio-Medicines, the business within Eli Lilly Company that comprises neuroscience and immunology. From 2014 to 2016, Ms. Shaw served as U.S. country head and President of Novartis Pharmaceutical Corporation, a global healthcare company, and from 2010 to 2014 as North American region head of Novartis Oncology. Prior to 2010, Ms. Shaw held several leadership positions at Johnson & Johnson, Inc. Ms. Shaw also serves as an executive board member of the Biotechnology Innovation Organization and is the co-founder of the More Moments More Memories Foundation to assist people with cancer and their caregivers. Ms. Shaw holds a B.B.A. in Marketing from Iowa State University and an M.B.A. from the University of Wisconsin.

What is the salary of Christi Shaw?

As the Independent Director of Avantor, the total compensation of Christi Shaw at Avantor is $278,129. There are 12 executives at Avantor getting paid more, with Michael Stubblefield having the highest compensation of $16,995,300.

How old is Christi Shaw?

Christi Shaw is 53, she's been the Independent Director of Avantor since 2018. There are 15 older and 12 younger executives at Avantor. The oldest executive at Avantor Inc. is Rajiv Gupta, 74, who is the Chairman of the Board.

What's Christi Shaw's mailing address?

Christi's mailing address filed with the SEC is C/O BEAM THERAPEUTICS INC.,, 238 MAIN STREET, CAMBRIDGE, MA, 02142.

Insiders trading at Avantor

Over the last 5 years, insiders at Avantor have traded over $3,149,576,044 worth of Avantor stock and bought 27,800 units worth $584,024 . The most active insiders traders include Mountain Investments Iii, L..., Jo Natauri oraz Sachs & Co. Llc Stone Bridg.... On average, Avantor executives and independent directors trade stock every 21 days with the average trade being worth of $48,107,115. The most recent stock trade was executed by Steven W Eck on 5 September 2024, trading 3,525 units of AVTR stock currently worth $88,337.

What does Avantor do?

based in center valley, pa (usa), avantor performance materials manufactures and markets high-performance chemistries and materials around the world under several respected brand names, including the j.t.baker®, macron fine chemicals™, rankem™, benesphera™, and poch™ brands. avantor products are used in a wide range of industries. our life sciences solutions are used in pharmaceutical production, laboratory research for academic, industry and quality control, and in medical lab testing. our electronics solutions are used in the manufacturing of semiconductors. for additional information please visit www.avantormaterials.com

Complete history of Ms. Shaw stock trades at Lilly(Eli) & Co, Avantor oraz Beam Therapeutics

Avantor executives and stock owners

Avantor executives and other stock owners filed with the SEC include:

• Michael Stubblefield,
  President, Chief Executive Officer, Director
• Thomas Szlosek,
  Chief Financial Officer, Executive Vice President
• Michael Stubblefield,
  Pres, CEO & Director
• Gerard Brophy,
  Executive Vice President - Biopharma Production
• Devashish Ohri,
  Executive Vice President - AMEA
• Frederic Vanderhaegen,
  Executive Vice President - Americas and Europe
• Thomas A. Szlosek,
  Exec. VP & CFO
• Frederic Vanderhaegen,
  Exec. VP of Americas & Europe
• Dr. Gerald Brophy Ph.D.,
  Exec. VP of Biopharma Production
• Michael Wondrasch,
  Exec. VP & Chief Information Officer
• Rajiv Gupta,
  Chairman of the Board
• Jonathan Peacock,
  Independent Director
• Christi Shaw,
  Independent Director
• Rakesh Sachdev,
  Independent Director
• Juan Andres,
  Independent Director
• Gregory Summe,
  Independent Director
• Michael Severino,
  Independent Director
• Jo Natauri,
  Director
• Andre Moura,
  Director
• Matthew Holt,
  Director
• Steven Eck,
  Senior Vice President, Chief Accounting Officer
• Mark Murray,
  Executive Vice President of the Biomaterials and Advanced Technologies Platform
• Sven Henrichwark,
  Executive Vice President of APAC
• Tanya Foxe,
  Executive Vice President - Global Operations and Supply Chain
• Christophe Couturier,
  Executive Vice President - Services, Strategy and Business Transformation
• James Bramwell,
  Executive Vice President - Strategic Partners
• Justin Miller,
  Executive Vice President, General Counsel, Secretary
• Michael Wondrasch,
  Executive Vice President, Chief Information Officer
• Eric McAllister,
  Chief Human Resource Officer, Executive Vice President
• Allison K. Hosak,
  Sr. VP of Global Communications & Brand
• Justin M. Miller Esq.,
  Exec. VP, Gen. Counsel & Sec.
• Tommy J. Thomas CPA,
  VP of Investor Relations
• Steven W. Eck,
  Sr. VP, Corp. Controller & Chief Accounting Officer
• Sheri Lewis,
  Exec. VP, Global Operations & Supply Chain
• Lan Kang,
  Director
• John Carethers,
  Director
• Sachs & Co. Llc Stone Bridg...,
  
• Sachs & Co. Llc Stone Bridg...,
  
• Sheri Lewis,
  EVP, Global Ops & Supply Chain
• Mountain Investments Iii, L...,
  
• Mala Murthy,
  Director
• Brittany Hankamer,
  EVP, Chief HR Officer
• Randy Lee Stone,
  EVP, Laboratory Solutions
• Corey Walker,
  President Laboratory Solutions
• Ashish Kulkarni,
  See Remarks
• Sachs & Co. Llcgoldman Sach...,
  
• Meghan Henson,
  EVP, Chief HR Officer
• Thomas Connolly,
  Director
• Joseph R Massaro,
  Director
• Kitty Sahin,
  EVP, Strategy&Corp Development
• Claudius Sokenu,
  EVP, Chief Legal & Compliance
• R. Brent Jones,
  EVP, Chief Financial Officer
• Benoit Gourdier,
  EVP, Biopharma Production